Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1337-1345

  Van Cutsem, Eric ^a   Findlay, Michael ^a   Osterwalder, Bruno ^a   Kocha, Walter ^a   Dalley, David ^a   Pazdur, Richard ^a   Cassidy, Jim ^a   Dirix, Luc ^a   Twelves, Chris ^a   Allman, David ^a   Seitz, Jean Francois ^a   Schölmerich, Jürgen ^a   Burger, Hans Ulrich ^a   Verweij, Jaap ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034016343     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1337     Document Type: Article

References (29)

1. The Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
2. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues. Eur J Cancer 34:1274-1281, 1998
3. Ishikawa T, Fukase Y, Yamamoto T, et al: Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 21:713-717, 1998
4. Ishikawa T, Utoh M, Sawada N, et al: Tumor selective delivery of 5-Fura by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097, 1998
5. Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110-1117, 1996
6. Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690, 1998
7. Cao S, Lu K, Ishitsuka H, et al: Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 16:226a, 1997 (abstr 795)
8. Schüller M, Cassidy J, Reigner B, et al: Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol (in press)
9. Budman DR, Meropol NJ, Reigner B, et al: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16:1795-1802, 1998
10. Mackean MJ, Planting AS, Twelves C, et al: A phase I and pharmacological study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985, 1998
11. Straw JA, Szapary D, Wynn WT: Pharmacokinetics of the diastereoisomer of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44:3114-3119, 1993
12. Cassidy J, Dirix L, Bisset D, et al: A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 4:2755-2761, 1998
13. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69:1375-1381, 1985
14. Findlay M, Van Cutsem E, Cocha W, et al: A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16:227a, 1997 (abstr 798)
15. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, Switzerland, 1979
16. Cunningham D, Findlay M: The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A:2077-2079, 1995
17. Advanced Colorectal Cancer Meta-analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960-969, 1994
18. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
19. De Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
20. Bleiberg H: Colorectal cancer: Is there an alternative to 5-FU? Eur J Cancer 33:536-541, 1997
21. Van Cutsem E: Raltitrexed (Tomudex). Exp Op Invest Drugs 7:823-834, 1998
22. Rougier P, Bugat R, Douillard J, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
23. Rougier Ph, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
24. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al: Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 35:54-59, 1999
25. Ducreux M, Louvet C, Bekradda M, et al: Oxaliplatin for the treatment of advanced colorectal cancer: Future directions. Semin Oncol 25:47-53, 1998
26. Weinerman B, Shah A, Fields A, et al: Systemic infusion versus bolus chemotherapy in measurable colorectal cancer. Am J Clin Oncol 15:518-523, 1992
27. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
28. Robben NC, Pippas AW, Moore JO: The syndrome of 5-fluorouracil cardiotoxicity. Cancer 71:493-509, 1993
29. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999